David Nash Net Worth

The estimated Net Worth of David Nash is at least $585 Mille dollars as of 24 May 2019. David Nash owns over 1,445 units of ANI Pharmaceuticals Inc stock worth over $284,420 and over the last 15 years he sold ANIP stock worth over $0. In addition, he makes $300,427 as Independent Director at ANI Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Nash ANIP stock SEC Form 4 insiders trading

David has made over 2 trades of the ANI Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 1,445 units of ANIP stock worth $99,358 on 24 May 2019.

The largest trade he's ever made was buying 1,445 units of ANI Pharmaceuticals Inc stock on 24 May 2019 worth over $99,358. On average, David trades about 74 units every 124 days since 2010. As of 24 May 2019 he still owns at least 5,236 units of ANI Pharmaceuticals Inc stock.

You can see the complete history of David Nash stock trades at the bottom of the page.

David Nash biography

Dr. David B. Nash M.D. serves as Independent Director of the Company. He is the founding dean emeritus of the Jefferson College of Population Health, and the Grandon Professor of Health Policy located on the campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008. Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College from 2003 until 2008. Dr. Nash also serves on the following privately held boards: InfoMC,Tract Manager and Fox Rehabilitation. Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement; his publications have appeared in many articles in major journals. Dr. Nash received his B.A. in economics (Phi Beta Kappa) from Vassar College; his M.D. from the University of Rochester School of Medicine and Dentistry and his M.B.A. in Health Administration (with honors) from the Wharton School at the University of Pennsylvania. Dr. Nash is currently a member of the Board’s Audit and Finance and Nominating and Corporate Governance Committees. If re-elected, Dr. Nash will serve as the Chair of the Board’s Nominating and Corporate Governance Committee, and will be a member of the Board’s Audit and Finance Committee. Dr. Nash is nominated for re-election based on his significant experience in both the life science industry and in academia that enhance the Board’s perspective on the pharmaceutical industry and his significant prior experience as an independent director.

What is the salary of David Nash?

As the Independent Director of ANI Pharmaceuticals Inc, the total compensation of David Nash at ANI Pharmaceuticals Inc is $300,427. There are 8 executives at ANI Pharmaceuticals Inc getting paid more, with Robert Schrepfer having the highest compensation of $2,160,980.

How old is David Nash?

David Nash is 64, he's been the Independent Director of ANI Pharmaceuticals Inc since 2019. There are 2 older and 12 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.

What's David Nash's mailing address?

David's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.

Insiders trading at ANI Pharmaceuticals Inc

Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... e Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.

What does ANI Pharmaceuticals Inc do?

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Complete history of David Nash stock trades at ANI Pharmaceuticals Inc e Humana

ANI Pharmaceuticals Inc executives and stock owners

ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Schrepfer,
  Senior Vice President - New Business Development and Specialty Sales
• Stephen Carey,
  Corporate Secretary, Vice President, Finance and Chief Financial Officer
• James Marken,
  Senior Vice President - Operations and Product Development
• James G. Marken,
  Sr. VP of Operations & Product Devel.
• Robert Brown,
  Independent Director
• Thomas Haughey,
  Independent Director
• Thomas Penn,
  Independent Director
• Patrick Walsh,
  Chairman of the Board
• David Nash,
  Independent Director
• Jeanne Thoma,
  Independent Director
• Antonio Pera,
  Independent Director
• Nikhil Lalwani,
  President, Chief Executive Officer, Director
• Muthasamy Shanmugam MS R.Ph.,
  Head of R&D and COO of Novitium Operations
• Ori Gutwerg,
  Sr. VP of Generics
• Christopher K. Mutz,
  Head of Rare Diseases
• Chad Gassert,
  Sr. VP of Corp. Devel. & Strategy
• Daniel Raynor,
  Director
• Arthur Przybyl,
  President and CEO
• Tracy Marshbanks,
  Director
• Fred Holubow,
  Director
• Peter A Lankau,
  Director
• Charlotte C. Arnold,
  Chief Financial Officer
• Renee P Tannenbaum,
  Director
• Ross J Mangano,
  Director
• Robert J. Jamnick,
  VP, Quality & Product Develop.
• Venture Partners Ii Lp Meri...,
  
• Ori Gutwerg,
  SVP, GENERICS
• Christopher Mutz,
  HEAD OF RARE DISEASE
• Krista Davis,
  SVP, CHIEF HR OFFICER
• Chad Gassert,
  SVP - CORP. DEV. & STRATEGY
• Meredith Cook,
  SR. VP, GENERAL COUNSEL & SEC.
• Muthusamy Shanmugam,
  HEAD OF R&D, COO-NOVITIUM OPS
• Matthew J Leonard,
  Director